Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

被引：0
|
作者：
Chang, Zhiwei [1 ]
Liu, Xiao-Lei [1 ]
Yu, Dan-Dan [1 ]
Han, Hui-Qiong [1 ]
He, Jian [1 ]
Wang, Rui-Rui [1 ]
Jia, Yong-Xu [1 ]
Yan, Jie [1 ]
Qin, Yanru [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16017
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wan-Rui
    Li, Xiaofen
    Tian, Bole
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial
    Jin, Shui-Ling
    Qiao, Shishi
    Li, Ren-Feng
    Zhang, Weijie
    He, Wei
    Su, Chang
    Li, Lu-Hao
    Pan, Jie
    Guo, Wen-Zhi
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 498 - 498
  • [24] A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC)
    Zhang, G.
    Hu, Y.
    Yang, B.
    Xu, Q.
    Li, J.
    Sun, S.
    Zhang, J.
    Jiao, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S722 - S722
  • [25] Toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: Preliminary results from a single-arm, open-label phase II trial
    Zhang, T.
    Yu, D.
    Wang, J.
    Liu, J.
    Ma, H.
    Lin, Z.
    Jin, M.
    Zhang, J.
    Zhao, L.
    Liu, H.
    Hu, J.
    Zhang, Q.
    ANNALS OF ONCOLOGY, 2021, 32 : S1057 - S1058
  • [26] Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
    Laoguo, Shi-xue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, GuangZhi
    Ma, Fuchao
    Peng, Tao
    Zeng, Zhiming
    Ma, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 576 - 576
  • [27] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
  • [28] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [29] Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.
    Du, Juan
    Tong, Fan
    Sha, Hui-zi
    Sun, Yi
    Zhu, Yahui
    Qi, Liang
    Li, Xiaoqin
    Li, Wei
    Yang, Yan
    Li, Zeqing
    Xu, Caihua
    Ni, Jiayao
    Gu, Qing
    Zhang, Xing
    Zhu, Chan
    Wang, Xiaoxuan
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
12345